Delcath Systems develops liver-directed cancer therapies, centered on its percutaneous hepatic perfusion platform. Its commercial product, HEPZATO KIT, delivers high-dose chemotherapy to the liver while limiting systemic exposure, used for metastatic uveal melanoma with unresectable hepatic metastases. The company serves oncology specialists and cancer centers focused on treating liver-dominant metastatic disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 24.2 | — | 2.7 | — |
| Q3 2025 | 20.6 | — | 0.8 | -50.6% |
| Q4 2025 | 20.7 | — | -1.9 | — |
| Q1 2026 | 25 | — | -1.1 | -206.8% |
| Q2 2026 | 29.1 | 20.6% | 2.7 | -1.1% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Evernorth Holdings, Inc. (XRPN), Ponce Financial Group, Inc. (PDLB), Farmers & Merchants Bancorp, Inc. (FMAO), Faeth Therapeutics, Inc. (FTH), Chilwa Minerals Limited (CHWM), Aclaris Therapeutics, Inc. (ACRS)